Text Size

Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00524641
First received: August 30, 2007
Last updated: July 8, 2009
Last verified: July 2009
History of Changes
  Purpose

To investigate the change in patient's asthma symptom control using ACQ scores after 4 to 6 weeks of Symbicort Turbuhaler (budesonide/ formoterol) in SMART approach.


Condition
Asthma

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Patient Follow-up Program to Assess Asthma Control in Patients Using Symbicort® as Maintenance and Relief Therapy in a Single Inhaler (Symbicort® SMART: Budesonide/Formoterol 160/4.5 Mcg, 1 or 2 Inhalations x 2 Times Plus Additional Inhalations as Needed)

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Enrollment: 1254
Study Start Date: July 2007
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Hospital out-patient departments and private clinics in all areas of Vietnam

Criteria

Inclusion Criteria:

  • Asthma patients from both sexes, age 18 or older
  • Have already been on Symbicort SMART treatment
  • Willing to give written informed consents to participate in the program.

Exclusion Criteria:

  • Patients who are not willing to give written informed consent
  • Patients in emergency care for asthma at ICUs or COPD patients are excluded from the program.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00524641

Locations
Vietnam
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Dinh Ngoc SY, MD TB and Lung Disease Hospital, Hanoi
Study Chair: Tran Van Ngoc, MD, PhD Cho Ray Hospital
Study Chair: Nguyen Hong Duc Pharm Ngoc Thach Hospital
Study Chair: Do Van Dung, MD, PhD Ho Chi Minh City Univ of Medicine and Pharmacist
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00524641     History of Changes
Other Study ID Numbers: NIS-RVN-SYM-2007/1, NIS-R84-AST-2007/3
Study First Received: August 30, 2007
Last Updated: July 8, 2009
Health Authority: Vietnam: Ho Chi Minh City Health Service

Keywords provided by AstraZeneca:
Asthma
Symbicort
NIS

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
 Hypersensitivity
Immune System Diseases
Symbicort
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 22, 2013